Organization
Nagoya University Hospital Clinical Oncology and Chemotherapy Lecturer of hospital
Title
Lecturer of hospital
Contact information
SHIMOKATA Tomoya
Degree 1
-
博士（医学） （ 2010.11 名古屋大学 ）
Research Interests 1
-
Clinical Oncology
Research Areas 1
-
Others / Others / Clinical Oncology
Current Research Project and SDGs 1
-
がん薬物療法における臨床薬理
Education 2
-
Nagoya University Graduate School, Division of Medical Sciences
- 2010.3
Country： Japan
-
Nagoya University Faculty of Medicine
- 2000.3
Country： Japan
Papers 22
-
Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer
Takano Yuko, Furune Satoshi, Miyai Yuki, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi
INTERNATIONAL CANCER CONFERENCE JOURNAL Vol. 11 ( 1 ) page： 67 - 70 2022.1
-
Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment (Oct, 10.1007/s13691-021-00515-w, 2021)
Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi
INTERNATIONAL CANCER CONFERENCE JOURNAL Vol. 11 ( 1 ) page： 49 - 49 2022.1
-
Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline.
Iwama S, Kobayashi T, Yasuda Y, Okuji T, Ito M, Ando M, Zhou X, Yamagami A, Onoue T, Kawaguchi Y, Miyata T, Sugiyama M, Takagi H, Hagiwara D, Suga H, Banno R, Hase T, Morise M, Wakahara K, Yokota K, Kato M, Nishio N, Tanaka C, Miyata K, Ogura A, Ito T, Sawada T, Shimokata T, Niimi K, Ohka F, Ishigami M, Gotoh M, Hashimoto N, Saito R, Kiyoi H, Kajiyama H, Ando Y, Hibi H, Sone M, Akiyama M, Kodera Y, Arima H
The Journal of clinical endocrinology and metabolism 2021.11
-
Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment
Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi
INTERNATIONAL CANCER CONFERENCE JOURNAL 2021.10
-
Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review
Kazama Shingo, Morimoto Ryota, Kimura Yuki, Shibata Naoki, Ozaki Reina, Araki Takashi, Mizutani Takashi, Oishi Hideo, Arao Yoshihito, Kuwayama Tasuku, Hiraiwa Hiroaki, Kondo Toru, Furusawa Kenji, Shimokata Tomoya, Okumura Takahiro, Bando Yasuko K., Ando Yuichi, Murohara Toyoaki
CARDIO-ONCOLOGY Vol. 7 ( 1 ) page： 26 2021.7
-
Guidelines for clinical evaluation of anti-cancer drugs
Minami Hironobu, Kiyota Naomi, Kimbara Shiro, Ando Yuichi, Shimokata Tomoya, Ohtsu Atsushi, Fuse Nozomu, Kuboki Yasutoshi, Shimizu Toshio, Yamamoto Noboru, Nishio Kazuto, Kawakami Yutaka, Nihira Shin-ichi, Sase Kazuhiro, Nonaka Takahiro, Takahashi Hideaki, Komori Yukiko, Kiyohara Koshin
CANCER SCIENCE Vol. 112 ( 7 ) page： 2563 - 2577 2021.7
-
A case of recurrent gastric cancer with drug-induced immune thrombocytopenia caused by trastuzumab
Takano Yuko, Furune Satoshi, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Osamu Maeda, Ando Yuichi
ANNALS OF ONCOLOGY Vol. 32 page： S354 - S354 2021.7
-
Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies
Minami Hironobu, Doi Toshihiko, Toyoda Masanori, Imamura Yoshinori, Kiyota Naomi, Mitsuma Ayako, Shimokata Tomoya, Naito Yoichi, Matsubara Nobuaki, Tajima Takeshi, Tokushige Kota, Ishihara Kae, Cameron Scott, Ando Yuichi
CANCER SCIENCE Vol. 112 ( 2 ) page： 725 - 733 2021.2
-
Chemotherapy for biliary tract cancer: real-world experience in a single institute
Maeda Osamu, Ebata Tomoki, Shimokata Tomoya, Matsuoka Ayumu, Inada-Inoue Megumi, Morita Sachi, Takano Yuko, Urakawa Hiroshi, Miyai Yuki, Sugishita Mihoko, Mitsuma Ayako, Ando Masahiko, Mizuno Takashi, Nagino Masato, Ando Yuichi
NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 82 ( 4 ) page： 725 - 733 2020.11
-
Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review
Maeda Osamu, Ohka Fumiharu, Maesawa Satoshi, Matsuoka Ayumu, Shimokata Tomoya, Mitsuma Ayako, Urakawa Hiroshi, Nakamura Shota, Shimoyamas Yoshic, Nakaguro Masato S., Wakabayashi Toshihiko, Ando Yuichi
NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 82 ( 4 ) page： 631 - 644 2020.11
-
5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Letter
Maeda Osamu, Shimokata Tomoya, Ando Yuichi
CLINICAL CANCER RESEARCH Vol. 26 ( 14 ) page： 3889 - 3889 2020.7
-
Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study
Urakawa Hiroshi, Ando Yuichi, Hase Tetsunari, Kikumori Toyone, Arai Eisuke, Maeda Osamu, Mitsuma Ayako, Sugishita Mihoko, Shimokata Tomoya, Ikuta Kunihiro, Ishiguro Naoki, Nishida Yoshihiro
INTERNATIONAL JOURNAL OF CANCER Vol. 146 ( 12 ) page： 3504 - 3515 2020.6
-
Detection of bacteria in blood circulation in patients receiving cancer chemotherapy.
Ota A, Morita S, Matsuoka A, Shimokata T, Maeda O, Mitsuma A, Yagi T, Asahara T, Ando Y
International journal of clinical oncology Vol. 25 ( 1 ) page： 210 - 215 2020.1
-
Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5 '-Deoxy-5-fluorocytidine, and Creatinine Clearance
Inaishi Takahiro, Fujita Ken-Ichi, Matsumoto Natsumi, Shimokata Tomoya, Maeda Osamu, Kikumori Toyone, Hattori Norifumi, Nakayama Goro, Ando Yuichi
IN VIVO Vol. 34 ( 6 ) page： 3539 - 3544 2020
-
Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma
Yonemori Kan, Kodaira Makoto, Satoh Taroh, Kudo Toshihiro, Takahashi Shunji, Nakano Kenji, Ando Yuichi, Shimokata Tomoya, Mori Joji, Inoue Koichi, Oakley Gerard J., Sakaguchi Sachi, Tamura Kenji
CANCER SCIENCE Vol. 109 ( 12 ) page： 3962 - 3970 2018.12
-
Reporting harms more transparently in trials of cancer drugs
Gyawali Bishal, Shimokata Tomoya, Honda Kazunori, Ando Yuichi
BMJ-BRITISH MEDICAL JOURNAL Vol. 363 page： k4383 2018.11
-
Outpatient chemotherapy for patients with unresectable or metastatic bone sarcomas
Urakawa Hiroshi, Nishida Yoshihiro, Mitsuma Ayako, Maeda Osamu, Sugishita Mihoko, Shimokata Tomoya, Mizutani Takeshi, Arai Eisuke, Ikuta Kunihiro, Hamada Shunsuke, Ota Takehiro, Ishiguro Naoki, Ando Yuichi
ANNALS OF ONCOLOGY Vol. 29 page： . 2018.10
-
Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan
Morita Sachi, Kikumori Toyone, Tsunoda Nobuyuki, Inaishi Takahiro, Adachi Yayoi, Ota Akiko, Shibata Masahiro, Matsuoka Ayumu, Nakanishi Kenichi, Takeuchi Dai, Mizutani Takefumi, Shimokata Tomoya, Hayashi Hironori, Maeda Osamu, Ando Yuichi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY Vol. 23 ( 1 ) page： 195 - 200 2018.2
-
Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan
Maeda O., Yokoyama Y., Yamaguchi J., Ota A., Matsuoka A., Morita S., Inoue M., Mizutani T., Shimokata T., Urakawa H., Mitsuma A., Nagino M., Ando Y.
ANNALS OF ONCOLOGY Vol. 28 page： 69-69 2017.11
-
Gemcitabine plus cisplatin and S-1 for biliary tract cancer: a single institute analysis
Maeda Osamu, Shimokata Tomoya, Mizutani Takefumi, Inoue Megumi, Matsuoka Ayumu, Ota Akiko, Mizuno Takashi, Ebata Tomoki, Nagino Masato, Ando Yuichi
ANNALS OF ONCOLOGY Vol. 28 page： 50-50 2017.10
-
Correlation and differences in Effect sizes between Progression Free Survival (PFS) and Overall Survival (OS) among PD-1 inhibitors
Gyawali B., Shimokata T., Ando Y.
ANNALS OF ONCOLOGY Vol. 28 page： . 2017.9
-
Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials. Reviewed
Bishal Gyawali, Tomoya Shimokata, Masahiko Ando, Kazunori Honda, Yuichi Ando
Annals of Oncology Vol. 28 ( 2 ) page： 246-253 2016.12
MISC 8
-
Chemotherapy in locally advanced head and neck squamous cell carcinoma Reviewed
Gyawali Bishal, Shimokata Tomoya, Honda Kazunori, Ando Yuichi
CANCER TREATMENT REVIEWS Vol. 44 page： 10-16 2016.3
-
Opioid-induced constipation. Reviewed
Gyawali B, Hayashi N, Tsukuura H, Honda K, Shimokata T, Ando Y
Scandinavian journal of gastroenterology Vol. 50 ( 11 ) page： 1331-8 2015
-
Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia. Reviewed
Shibata T, Minami Y, Mitsuma A, Morita S, Inada-Inoue M, Oguri T, Shimokata T, Sugishita M, Naoe T, Ando Y
International journal of clinical oncology Vol. 19 ( 2 ) page： 391-6 2014.4
-
Carboplatin dosing for adult Japanese patients. Reviewed
Ando Y, Shimokata T, Yasuda Y, Hasegawa Y
Nagoya journal of medical science Vol. 76 ( 1-2 ) page： 1-9 2014.2
-
Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. Reviewed
Oguri T, Mitsuma A, Inada-Inoue M, Morita S, Shibata T, Shimokata T, Sugishita M, Nakayama G, Uehara K, Hasegawa Y, Ando Y
International journal of clinical pharmacology and therapeutics Vol. 51 ( 6 ) page： 475-81 2013.6
-
Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer. Reviewed
Morita S, Uehara K, Nakayama G, Shibata T, Oguri T, Inada-Inoue M, Shimokata T, Sugishita M, Mitsuma A, Ando Y
Cancer chemotherapy and pharmacology Vol. 71 ( 2 ) page： 405-11 2013.2
-
Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Reviewed
Shimokata T, Ando Y, Yasuda Y, Hamada A, Kawada K, Saito H, Matsuo S, Kondo M, Imaizumi K, Hasegawa Y
Cancer science Vol. 101 ( 12 ) page： 2601-5 2010.12
-
Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Reviewed
Oguri T, Shimokata T, Inada M, Ito I, Ando Y, Sasaki Y, Hasegawa Y
Cancer chemotherapy and pharmacology Vol. 66 ( 4 ) page： 813-7 2010.9
KAKENHI (Grants-in-Aid for Scientific Research) 5
-
がん薬物療法における抗がん薬曝露に対する科学的エビデンスの創出
Grant number：19K07083 2019.4 - 2023.3
科学研究費助成事業 基盤研究(C)
満間 綾子, 安藤 雄一, 下方 智也
Authorship：Coinvestigator(s)
新規抗がん薬の開発により、外来化学療法で取り扱う抗がん薬レジメンは増加する一方である。外来化学療法室の利用患者は年々増加し、多様なニーズに応えるがん薬物療法に習熟した医療者の関わりが重要となっている。がん薬物療法を専門とする医療者の育成、拡充にあたっては、専門的な教育・訓練とともに抗がん薬を扱う現場における医療者の安全、職場環境の整備も提唱されている。曝露防止のための機器開発が進む中で過去の報告は現状と乖離しており、医療者がコストと時間をかけてどこまで曝露対策を行うかの科学的実証は未確立である。本研究では、抗がん薬曝露の実態を経年的・経時的に調査し現状に即したエビデンスを創出する。
本研究では、がん薬物療法における抗がん薬曝露の実態を調査し、繰り返しモニタリングを行うことで、国内での閾値の設定や予防の根拠となるエビデンスを創出することを目的としている。当院外来化学療法室では、院内すべての点滴抗がん薬の外来投与を専任の医療者が担当している。年間10000件以上の実施にあたり、職業性曝露のモニタリングとして環境モニタリングと生物学的モニタリングの経年的実施を行う。
＜環境モニタリング＞
当院外来化学療法室での環境モニタリングを行うにあたり、モニタリングの手法、場所を絞り込んだ後に、抗がん薬曝露予防を目的とした機器導入、マニュアルの改訂・整備の現状を把握できている。閉鎖式薬物移送システム(closed system drug transfer device: CSTD) は、当院において抗がん薬のミキシングすべてには使用していない。揮発性抗がん薬にのみCSTDを使用している。これまでのモニタリング結果では既報に比べて汚染の度合いを示す測定値は低く、現状での手法により経時的にモニタリングを進めている。
＜生物学的モニタリング＞
外来化学療法室で実施する膀胱内注入後の抗がん薬曝露について、同意を得た患者および医療者の排尿より生物学的モニタリングを行う。ドキソルビシンの投与が予定されており、投与量、排尿回数など臨床薬理学的解析を加えて経時的変化を観察する予定であったが、治療対象者が乏しい状況が続いている。がん関連学会での情報収集を継続した。侵襲の程度が少ない新たな手法（唾液検体からの検出）では検体量の採取に時間がかかることが判明した。
環境モニタリングは順調に推移している。昨年同様、生物学的モニタリングは対象患者が乏しい状況があった。新規薬剤の導入やCOVID-19により高齢患者など地元での治療ニーズが高い影響を考える。
生物学的モニタリングの対象となる泌尿器疾患の患者が減少している。新規薬剤の導入やCOVID-19による影響が考えられ、今後の増加は難しい状況である。研究代表者および研究分担者との討議を定期的に行っており、引き続き現状での研究の推進に努める。 -
Mechanism of diarrhea/enteritis caused by anticancer drugs and development of new treatment
Grant number：17K08950 2017.4 - 2020.3
Ando Yuichi
Authorship：Coinvestigator(s)
By focusing on bacterial-translocation, phenomenon in which human intestinal bacteria migrate into circulating blood in human body via intestinal wall, using highly-sensitive detection assay for viable bacteria, I investigated whether bacteria in the blood would be associated with the occurrence of adverse effects of cancer chemotherapy. The results revealed that patients with cancer were always prone to bacterial-translocations regardless of the administration of anticancer drugs, suggesting that bacterial-translocation would be the cause of febrile neutropenia, infection, and diarrhea/enteritis, which are caused by cancer chemotherapy.
-
Screening and prevention of vascular events for cancer patients, and investigation of the mechanisms.
Grant number：16K08906 2016.4 - 2020.3
Mitsuma Ayako
Authorship：Coinvestigator(s)
Some newly developed cancer chemotherapy drugs cause hemorrhage or thrombosis as adverse event through inhibition of angiogenesis. Prolonged survival and aging of cancer patients lead to increase of patients using anticoagulats to prevent cardiovascular disease. In this study we evaluated risk of cancer associated thrombosis receiving outpatient treatment, including drug interactions. We compared our data with predictive model proposed in foreign studies. We found no difference in outcome of treatment with specific anticoagulants. Effects of cancer chemotherapy and condition of patients influenced clinical course of thrombosis.
-
Elucidation of sarcopenia mechanism in the cancer cachexia
Grant number：15K08906 2015.4 - 2019.3
Shimokata Tomoya
Authorship：Principal investigator
Grant amount：\4810000 （ Direct Cost: \3700000 、 Indirect Cost：\1110000 ）
We evaluated the body composition, muscle mass and adipose tissue, in patients who received cancer pharmacotherapy to test a hypothesis that the adipose tissue plays an important role in the process to cancer cachexia. We analyzed the change of the body composition in patients who received monotherapy of the mTOR inhibitor more than six months retrospectively. The muscle mass significantly decreased, but there were no significant changes in the adipose tissue quantity. Also, we performed a cohort study to evaluate a body composition change and a metabolic rate as subjects in the patients prospectively. We accumulate 28 cases and final analysis is in progress.
-
Clinical significance of sarcopenia in cancer chemotherapy
Grant number：26460626 2014.4 - 2018.3
Ando Yuichi
Authorship：Coinvestigator(s)
The aim of this study is investigated sarcopenia in cancer patients who underwent cancer chemotherapy in order to test the hypothesis that those patients with sarcopenia are more likely to experience severe toxicity and then poorly tolerate the treatment. First, we retrospectively analyzed the change of skeletal muscle mass in patients treated with an mTOR inhibitor and reported that the muscle mass was significantly reduced by treatment. Subsequently, an observational study was conducted to prospectively evaluate sarcopenia up to for 6 months in cancer patients who received a kinase inhibitor containing mTOR inhibitor. Of the 28 patients enrolled, 17 and 7 patients completed the 6-month and 3-month follow-ups, respectively. Final analysis of the results is in progress.
Teaching Experience (On-campus) 5
-
臨床腫瘍学入門
2021
-
臨床腫瘍学入門
2020
-
臨床腫瘍学入門
2019
-
臨床腫瘍学入門
2018
-
臨床腫瘍学入門
2017